FDA clears Adherium’s usage tracker for AstraZeneca inhaler

Patients may view their medication usage data on the Smartinhaler app. (Adherium)

Australian smart inhaler maker Adherium has scored an FDA nod for its SmartTouch device, for use with AstraZeneca’s Symbicort aerosol inhalers.

Designed to improve medication adherence, the SmartTouch device attaches to a patient’s inhaler and tracks the date and time that it is used. It then transmits this data to an app on a smartphone or tablet. Physicians can look at a patient’s usage trends to tailor his or her treatment plan.

“The SmartTouch for Symbicort is the most advanced Smartinhaler product to date for Adherium and a key product in our strategic collaboration with AstraZeneca by bringing the benefits of digital monitoring to patients and their physicians,” said Adherium CEO Arik Anderson, in a statement.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

The FDA clearance is Adherium’s third. Its Smartinhaler offerings include devices and apps that help patients manage respiratory disease.

RELATED: Health, environmental tracker could head off asthma attacks without drugs

The device can be used in home monitoring programs—such as those geared at preventing hospital readmission—where drug adherence after hospital discharge is an important goal, Adherium said in the statement.

In 2015, the companies announced a nonexclusive agreement under which Adherium would supply AstraZeneca with smart inhalers for use with any combination of budesonide and formoterol, the active ingredients in the Symbicort product. The next month, AstraZeneca backed Adherium in its IPO.

Suggested Articles

Avidity Biosciences is on a roll—after inking an R&D deal with Eli Lilly and hiring a new CEO, the company is reeling in $100 million.

What the NASH field needs, says Genfit CEO Pascal Prigent, is something like the Hb1Ac test for diabetes.

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.